- Email: [email protected]
Clinical efficacy of a dermocosmetic skin lightening cream in woman suffering from melasma
3720
3706
Automated microneedling and topical 5-flurouracil solution may help in treating acral vitiligo Hasan El-Fakahany, MD, Minia University, Minia, Egypt; Hamza Abdel Raouf, MD, Minia University, Minia, Egypt; Walid Medhat, MD, Minia University, Minia, Egypt
Clinical and instrumental efficacy of a dermocosmetic with Uniwhite peptide, niacinamide, vitC and hyaluronic acid on reducing actinic lentigo and improving photoaging Ana Beatris Rossi, MD, PFCD, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France
Introduction: Acral vitiligo is considered one of the most distressing dermatological disorders. Although surgical treatment is considered the treatment of choice in these patients after disease stability, yet it is time, cost and effort consuming. It also needs skillful experience. Microneedling was used with little success for treating acral vitiligo either solely or combined with excimer laser. Aim of the study: An automated microneedling device has been tried to induce repigmentation in stable acral vitiligo patches. 5-Flurouracil is used topically during the procedure. Patients and methods: Twenty patients with stable acral vitiligo were treated with an automated microneedling device in combination with topical 5-flurouracil solution. Each patient received sessions every 2 weeks. Results: Repigmentation was noticed in sixteen patients after variable number of sessions. Conclusion: Automated microneedling with topical 5-flurouracil solution may provide a simple, effective method for treating resistant and stable cases of acral vitiligo. Commercial support: None identified.
Introduction: This monocentric open-label study assessed the clinical and instrumental efficacy and tolerability of a night cream containing uniwhite peptide (2%), niacinamide (4%), vitamin C derivative (4%) and hyaluronic acid (0.1%) for photoaging skin applied once daily during 8 weeks. Methods: Forty-six white volunteers were included 53 to 70 yo. At inclusion, subjects presenting crow’s feet wrinkles graded 2 to 6 (0- 8 scale) and at least one facial target lentigo. Product was applied on the face and neck. Assessments were performed at baseline, after 4 and 8 weeks: Clinical evaluation of wrinkles, facial complexion homogeneity & luminosity; instrumental evaluation of lentigo intensity and sharpness, wrinkles depth and melanin content Subjects answered a questionnaire at each postbaseline visit. Results: All subjects completed the study. Mean age was 64 yo. In vivo evaluation showed a significant progressive improvement in skin luminosity, complexion homogeneity and crow’s foot wrinkles depth, at each visit (P \.05). These results were confirmed by clinical evaluation on digital photographs with significant improvement of the lentigo, complexion homogeneity, lightening effect and facial complexion. Lentigo software analysis (n ¼ 39) showed a significant decrease of the color contrast between lentigo and surrounding skin, as well as a decrease in the target area indicating a depigmenting effect on target lentigo (P \.005). A decrease in melanin component was also observed at each visit (P \ .001), confirming a lightening effect of the product. From the first visit, 80% of subjects considered that the product had a redensifying effect and 91% felt a deeply nourished skin. Conclusion: In this 8-week study, this face and neck night cream containing peptide, niacinamide, ascorbic glucoside and hyaluronic acid, was well tolerated and effective to improve actinic lentigo and clinical aspects of photoaging, both through clinical in vivo and instrumental noninvasive evaluation. Supported by PFDC.
3439
3703
Clinical and instrumental efficacy of a dermo-cosmetic serum with azelawhite complex and glycolic acid on reducing actinic lentigo and improving photoaging Ana Beatris Rossi, MD, PFCD, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France Introduction: The aim of this open-label clinical study was to assess the clinical and instrumental efficacy and tolerability in use conditions of a serum containing azelawhite complex (2% of peptide and 8% of azelaic acid) and glycolic acid (3%) for photoaged skin during 12 weeks. We have already demonstrated the ‘‘antiaging’’ effect of this association on human cutaneous explants. Methods: Forty-two white volunteers (45 to 70 yo) were included in this monocentric open-label clinical study. At inclusion, subjects presented periorbital wrinkles graded 3 to 6 (1-9 scale) and at least one target lentigo. The tested product was applied on the face and neck twice daily. At baseline and after 4, 8 and 12 weeks of product use, clinical and instrumental assessments of photoaging signs of the face were performed. At each visit, a board certified dermatologist evaluated subjects’ skin for clinical tolerability and graded a target lentigo according a modified MASI. Instrumental chromameter measurements of the skin color (ITA), 3-D skin surface profile (AEVA) and skin elasticity (cutometer) were performed. Macroscopic high definition images of the skin were taken with DermLite. Subjects answered a questionnaire at each postbaseline visit.
Clinical efficacy of a dermocosmetic skin lightening cream in woman suffering from melasma Ana Beatris Rossi, MD, PFDC, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France Introduction: The aim of this intraindividual comparative study was to assess the clinical and instrumental efficacy of a skin lightening cream containing azelaic acid (12%) and glycolic acid (5.2%) for melasma during 16 weeks. The dermatologic safety of the product and the quality of life impact on subjects were also evaluated.
Results: All subjects completed the study. Mean age was 57 yo. The local MASI score for the target lentigo improved significantly after 4, 8 and 12 weeks (P\.001). These clinical results were confirmed by instrumental evaluation, with a significant increase of ITA values indicating a lighter color of the lentigo at each visit (P \ .001), as well as the color contrast analysis of the lentigo images compared to the surrounding skin (P \.001). AEVA assessment showed a significant improvement of the rough structures (deep wrinkles) after 4 weeks of product use (P ¼ .008). Product was considered efficacious in reducing photoaging signs by 62% of subjects at week 4 and 67% at week 12.
Methods: Thirty-three females’ volunteers were included. The tested product was applied twice-daily on face hyperpigmented affected area. This melasma treated area was compared to healthy unaffected area at all assessment time (at baseline and after 8, 12 and 16 weeks (W)). Primary parameter was the clinical assessment of the modified MASIa compared to uninvolved skin. Instrumental chromameter measurement (ITA8 value), macrophotographies and image ranking scoring using 4 pointscale (1 ¼ least melasma to 4 ¼ strongest melasma) were also performed. Quality of life was assessed with MelasQoL scale. Product tolerance was also assess by the dermatologist during the study. Results: Thirty-one subjects (mean age: 47 years old) presenting combined (epidermal and dermal) or dermal melasma (as selected by Wood lamp) were analyzed. Two subjects have been withdrawn without relation with the tested product. The modified MASI score improved significantly after 8, 12 and 16 weeks (2.6; 2.1; 1.5) compared to baseline (3.8) (P \ .001). The clinical scoring of macrophotographies also showed the decrease of melasma severity from strongest to least (P \ .001). The parameter skin tan value (ITA8) by chromametric measurement confirmed the clinical assessment. A significant progressive decrease of the color difference between the melasma treated area and the surrounding nonpigmented area was observed from W8 to W16 (P \.001). The significant decrease of the MelasQoL score from 27.9 at baseline to 18.6 at W16 showed the improvement of the subjects’ quality of life (P \ .001). The skin tolerance was judged ‘‘good’’ by the dermatologist.
Conclusion: The twice-daily application of a serum containing azelawhite complex and glycolic acid over 12 weeks, was well tolerated and improved clinical aspects of photoaged skin, confirmed by dermatologist, Subjects and instrumental noninvasive evaluation.
Conclusion: The twice-daily application of a dermocosmetic cream containing azelaic and glycolic acids over 16 weeks improved clinical severity of melasma pigmented areas through dermatologist, subjects and instrumental evaluations, with a good tolerance.
Supported by PFDC.
Supported by PFDC.
MAY 2016
J AM ACAD DERMATOL
AB231
3706
Automated microneedling and topical 5-flurouracil solution may help in treating acral vitiligo Hasan El-Fakahany, MD, Minia University, Minia, Egypt; Hamza Abdel Raouf, MD, Minia University, Minia, Egypt; Walid Medhat, MD, Minia University, Minia, Egypt
Clinical and instrumental efficacy of a dermocosmetic with Uniwhite peptide, niacinamide, vitC and hyaluronic acid on reducing actinic lentigo and improving photoaging Ana Beatris Rossi, MD, PFCD, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France
Introduction: Acral vitiligo is considered one of the most distressing dermatological disorders. Although surgical treatment is considered the treatment of choice in these patients after disease stability, yet it is time, cost and effort consuming. It also needs skillful experience. Microneedling was used with little success for treating acral vitiligo either solely or combined with excimer laser. Aim of the study: An automated microneedling device has been tried to induce repigmentation in stable acral vitiligo patches. 5-Flurouracil is used topically during the procedure. Patients and methods: Twenty patients with stable acral vitiligo were treated with an automated microneedling device in combination with topical 5-flurouracil solution. Each patient received sessions every 2 weeks. Results: Repigmentation was noticed in sixteen patients after variable number of sessions. Conclusion: Automated microneedling with topical 5-flurouracil solution may provide a simple, effective method for treating resistant and stable cases of acral vitiligo. Commercial support: None identified.
Introduction: This monocentric open-label study assessed the clinical and instrumental efficacy and tolerability of a night cream containing uniwhite peptide (2%), niacinamide (4%), vitamin C derivative (4%) and hyaluronic acid (0.1%) for photoaging skin applied once daily during 8 weeks. Methods: Forty-six white volunteers were included 53 to 70 yo. At inclusion, subjects presenting crow’s feet wrinkles graded 2 to 6 (0- 8 scale) and at least one facial target lentigo. Product was applied on the face and neck. Assessments were performed at baseline, after 4 and 8 weeks: Clinical evaluation of wrinkles, facial complexion homogeneity & luminosity; instrumental evaluation of lentigo intensity and sharpness, wrinkles depth and melanin content Subjects answered a questionnaire at each postbaseline visit. Results: All subjects completed the study. Mean age was 64 yo. In vivo evaluation showed a significant progressive improvement in skin luminosity, complexion homogeneity and crow’s foot wrinkles depth, at each visit (P \.05). These results were confirmed by clinical evaluation on digital photographs with significant improvement of the lentigo, complexion homogeneity, lightening effect and facial complexion. Lentigo software analysis (n ¼ 39) showed a significant decrease of the color contrast between lentigo and surrounding skin, as well as a decrease in the target area indicating a depigmenting effect on target lentigo (P \.005). A decrease in melanin component was also observed at each visit (P \ .001), confirming a lightening effect of the product. From the first visit, 80% of subjects considered that the product had a redensifying effect and 91% felt a deeply nourished skin. Conclusion: In this 8-week study, this face and neck night cream containing peptide, niacinamide, ascorbic glucoside and hyaluronic acid, was well tolerated and effective to improve actinic lentigo and clinical aspects of photoaging, both through clinical in vivo and instrumental noninvasive evaluation. Supported by PFDC.
3439
3703
Clinical and instrumental efficacy of a dermo-cosmetic serum with azelawhite complex and glycolic acid on reducing actinic lentigo and improving photoaging Ana Beatris Rossi, MD, PFCD, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France Introduction: The aim of this open-label clinical study was to assess the clinical and instrumental efficacy and tolerability in use conditions of a serum containing azelawhite complex (2% of peptide and 8% of azelaic acid) and glycolic acid (3%) for photoaged skin during 12 weeks. We have already demonstrated the ‘‘antiaging’’ effect of this association on human cutaneous explants. Methods: Forty-two white volunteers (45 to 70 yo) were included in this monocentric open-label clinical study. At inclusion, subjects presented periorbital wrinkles graded 3 to 6 (1-9 scale) and at least one target lentigo. The tested product was applied on the face and neck twice daily. At baseline and after 4, 8 and 12 weeks of product use, clinical and instrumental assessments of photoaging signs of the face were performed. At each visit, a board certified dermatologist evaluated subjects’ skin for clinical tolerability and graded a target lentigo according a modified MASI. Instrumental chromameter measurements of the skin color (ITA), 3-D skin surface profile (AEVA) and skin elasticity (cutometer) were performed. Macroscopic high definition images of the skin were taken with DermLite. Subjects answered a questionnaire at each postbaseline visit.
Clinical efficacy of a dermocosmetic skin lightening cream in woman suffering from melasma Ana Beatris Rossi, MD, PFDC, Toulouse, France; Therese Nocera, MD, PFDC, Toulouse, France; Priscilla Lapallud, PhD, PFDC, Toulouse, France Introduction: The aim of this intraindividual comparative study was to assess the clinical and instrumental efficacy of a skin lightening cream containing azelaic acid (12%) and glycolic acid (5.2%) for melasma during 16 weeks. The dermatologic safety of the product and the quality of life impact on subjects were also evaluated.
Results: All subjects completed the study. Mean age was 57 yo. The local MASI score for the target lentigo improved significantly after 4, 8 and 12 weeks (P\.001). These clinical results were confirmed by instrumental evaluation, with a significant increase of ITA values indicating a lighter color of the lentigo at each visit (P \ .001), as well as the color contrast analysis of the lentigo images compared to the surrounding skin (P \.001). AEVA assessment showed a significant improvement of the rough structures (deep wrinkles) after 4 weeks of product use (P ¼ .008). Product was considered efficacious in reducing photoaging signs by 62% of subjects at week 4 and 67% at week 12.
Methods: Thirty-three females’ volunteers were included. The tested product was applied twice-daily on face hyperpigmented affected area. This melasma treated area was compared to healthy unaffected area at all assessment time (at baseline and after 8, 12 and 16 weeks (W)). Primary parameter was the clinical assessment of the modified MASIa compared to uninvolved skin. Instrumental chromameter measurement (ITA8 value), macrophotographies and image ranking scoring using 4 pointscale (1 ¼ least melasma to 4 ¼ strongest melasma) were also performed. Quality of life was assessed with MelasQoL scale. Product tolerance was also assess by the dermatologist during the study. Results: Thirty-one subjects (mean age: 47 years old) presenting combined (epidermal and dermal) or dermal melasma (as selected by Wood lamp) were analyzed. Two subjects have been withdrawn without relation with the tested product. The modified MASI score improved significantly after 8, 12 and 16 weeks (2.6; 2.1; 1.5) compared to baseline (3.8) (P \ .001). The clinical scoring of macrophotographies also showed the decrease of melasma severity from strongest to least (P \ .001). The parameter skin tan value (ITA8) by chromametric measurement confirmed the clinical assessment. A significant progressive decrease of the color difference between the melasma treated area and the surrounding nonpigmented area was observed from W8 to W16 (P \.001). The significant decrease of the MelasQoL score from 27.9 at baseline to 18.6 at W16 showed the improvement of the subjects’ quality of life (P \ .001). The skin tolerance was judged ‘‘good’’ by the dermatologist.
Conclusion: The twice-daily application of a serum containing azelawhite complex and glycolic acid over 12 weeks, was well tolerated and improved clinical aspects of photoaged skin, confirmed by dermatologist, Subjects and instrumental noninvasive evaluation.
Conclusion: The twice-daily application of a dermocosmetic cream containing azelaic and glycolic acids over 16 weeks improved clinical severity of melasma pigmented areas through dermatologist, subjects and instrumental evaluations, with a good tolerance.
Supported by PFDC.
Supported by PFDC.
MAY 2016
J AM ACAD DERMATOL
AB231